25 June 2026
25 June 2026
RQ Bio’s lead asset, RQB01, is currently in IND-enabling studies.
Primary objectives involve assessing the tolerability, pharmacokinetics and safety of VK3019.
The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour disease.
Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
